Astrazeneca starts Phase 3 for BREZTRI to improve cardiopulmonary outcomes in COPD

 THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD

First patients dosed in ATHLOS Phase III trial assessing impact of BREZTRI on integrated cardiopulmonary parameters associated with health status and survival in patients with COPD

https://finance.yahoo.com/news/astrazeneca-announces-initiation-tharros-phase-110600738.html